MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
45.00
-2.09
-4.44%
Pre Market: 45.15 +0.15 +0.33% 06:18 12/15 EST
OPEN
46.98
PREV CLOSE
47.09
HIGH
47.13
LOW
44.50
VOLUME
60
TURNOVER
0
52 WEEK HIGH
48.26
52 WEEK LOW
1.865
MARKET CAP
4.78B
P/E (TTM)
-43.6131
1D
5D
1M
3M
1Y
5Y
1D
Why Terns Pharmaceuticals (TERN) Is Up 73.6% After Upsized Equity Raise On Strong TERN-701 Data
Simply Wall St · 3d ago
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Barchart · 3d ago
Terns Pharmaceuticals Is Maintained at Market Outperform by Citizens
Dow Jones · 3d ago
Citizens Maintains Market Outperform on Terns Pharma, Raises Price Target to $57
Benzinga · 3d ago
Terns Pharmaceuticals Announces Major Stock Offering
TipRanks · 3d ago
Terns Pharmaceuticals price target raised to $57 from $35 at Citizens
TipRanks · 4d ago
Midday Fly By: SK Hynix weighs U.S. listing, GE Vernova doubles dividend
TipRanks · 4d ago
Terns Pharmaceuticals Stock Rises on Public Offerings to Fund TERN-701
Dow Jones · 4d ago
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.